<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615105</url>
  </required_header>
  <id_info>
    <org_study_id>18-224</org_study_id>
    <nct_id>NCT03615105</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to learn whether a new method to prevent rejection between the donor&#xD;
      immune system and the patient's body is effective.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will receive one of three myeloablative conditioning regimens followed by a Alpha/beta+ T-cell depleted peripheral blood stem cell product and short course tacrolimus. Donors are HLA mismatched unrelated adults or haploidentical family members.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of incidences of grade 3-4 acute GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>The intervention will be considered unpromising if the rate of GVHD is greater than 40% and promising if the rate is 20% or less.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Acute Lymphoid Leukemia (ALL)</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Radiation, Thiotepa &amp; Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan, Fludarabine &amp; Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clofarabine, Thiotepa &amp; Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperfractionated total body irradiation</intervention_name>
    <description>Hyperfractionated TBI is administered by a linear accelerator at a dose rate of &lt;20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).</description>
    <arm_group_label>Radiation, Thiotepa &amp; Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa 5 mg/kg IV</description>
    <arm_group_label>Clofarabine, Thiotepa &amp; Melphalan</arm_group_label>
    <arm_group_label>Radiation, Thiotepa &amp; Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 60 mg/kg IV</description>
    <arm_group_label>Radiation, Thiotepa &amp; Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan (adult/ped dose)</description>
    <arm_group_label>Busulfan, Fludarabine &amp; Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 25 mg/m2 IV</description>
    <arm_group_label>Busulfan, Fludarabine &amp; Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 70 mg/m2 IV</description>
    <arm_group_label>Busulfan, Fludarabine &amp; Melphalan</arm_group_label>
    <arm_group_label>Clofarabine, Thiotepa &amp; Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Clofarabine 20-30 mg/m2 IV</description>
    <arm_group_label>Clofarabine, Thiotepa &amp; Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HPC(A) stem cell allograft</intervention_name>
    <description>All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.</description>
    <arm_group_label>Busulfan, Fludarabine &amp; Melphalan</arm_group_label>
    <arm_group_label>Clofarabine, Thiotepa &amp; Melphalan</arm_group_label>
    <arm_group_label>Radiation, Thiotepa &amp; Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 200 mg IV flat dose</description>
    <arm_group_label>Busulfan, Fludarabine &amp; Melphalan</arm_group_label>
    <arm_group_label>Clofarabine, Thiotepa &amp; Melphalan</arm_group_label>
    <arm_group_label>Radiation, Thiotepa &amp; Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rabbit antithymocyte globulin</intervention_name>
    <description>Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.</description>
    <arm_group_label>Busulfan, Fludarabine &amp; Melphalan</arm_group_label>
    <arm_group_label>Clofarabine, Thiotepa &amp; Melphalan</arm_group_label>
    <arm_group_label>Radiation, Thiotepa &amp; Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion Criteria:&#xD;
&#xD;
          -  Patients with any of the following hematologic malignancies who are considered to be&#xD;
             eligible for allogeneic transplantation:&#xD;
&#xD;
               -  Acute lymphoid leukemia (ALL) in first complete remission (CR1) with high risk&#xD;
                  for relapse including:&#xD;
&#xD;
                    -  Detectable minimal residual disease by either multicolor flow cytometry or&#xD;
                       by genomic assay after initial induction therapy&#xD;
&#xD;
                    -  t(9;22) or detected BCR-ABL1 translocation by genomic methodologies&#xD;
&#xD;
                    -  BCR-ABL1-Like B-ALL [23] including mutations of IKZF1 or CRLF2&#xD;
&#xD;
                    -  Translocations or mutations involving 11q23 (MLL) gene.&#xD;
&#xD;
                    -  Hypodiploid karyotype&#xD;
&#xD;
                    -  Deletion of 9p&#xD;
&#xD;
                    -  Loss of 17p or TP53 mutation&#xD;
&#xD;
                    -  T-lymphocyte lineage antigen expression (T-ALL)&#xD;
&#xD;
                    -  Prior CNS or other extramedullary involvement&#xD;
&#xD;
                    -  WBC count ≥ 100,000 cells/μL at diagnosis&#xD;
&#xD;
                    -  Acute biphenotypic or bilineal leukemia in CR1&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) in CR1 with&#xD;
&#xD;
                    -  Detectable minimal residual disease (MRD) by either multicolor flow&#xD;
                       cytometry or by genomic assay after initial induction therapy&#xD;
&#xD;
                    -  In the absence of MRD any intermediate or high risk features according to&#xD;
                       the European LeukemiaNet 2017 guidelines indlucing:&#xD;
&#xD;
          -  Mutated FL T3-ITD or FL T3-TKD&#xD;
&#xD;
          -  Cytogenetic abnormalities not classified as favorable&#xD;
&#xD;
          -  Cytogenetic abnormalities associated with myelodysplastic syndrome including&#xD;
             abnormalities of chromosome 5, 7, or 17p&#xD;
&#xD;
          -  Complex karyotype or monosomal karyotype&#xD;
&#xD;
          -  t(9;11)(p21.1;q23.3); MLL-KMT2A or other rearrangements of KMT2A&#xD;
&#xD;
          -  t(9;11); BCR-ABL1&#xD;
&#xD;
          -  Inversions or translocations of chromosome 3&#xD;
&#xD;
          -  T(6;9)(p23;q34.1); DEK-NUP214&#xD;
&#xD;
          -  Somatic mutation of RUNX1, ASX1 or TP53&#xD;
&#xD;
               -  Extramedullary involvement&#xD;
&#xD;
               -  WBC count ≥100,000 cells/μL at diagnosis&#xD;
&#xD;
                    -  Relapsed acute leukemia with ≤ 5% blasts in the bone marrow prior to&#xD;
                       transplantation (i.e. CR2 or greater).&#xD;
&#xD;
                    -  Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap&#xD;
                       syndrome with ≤ 10% blasts and at least one of the following:&#xD;
&#xD;
               -  Revised International Prognostic Scoring System risk score of INT, HIGH, or VERY&#xD;
                  HIGH at the time of transplant evaluation.&#xD;
&#xD;
               -  Life-threatening cytopenias&#xD;
&#xD;
               -  Karyotype or genomic changes that indicate high risk for progression to acute&#xD;
                  myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of&#xD;
                  TP53, or complex or monosomal karyotype.&#xD;
&#xD;
               -  Therapy related disease or disease evolving from other malignant processes.&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia (CMML) with ≤ 10% blasts prior to&#xD;
                       transplantation.&#xD;
&#xD;
                    -  Chronic myeloid leukemia (CML) meeting one of the following criteria:&#xD;
&#xD;
               -  Failed or are intolerant to BCR-ABL tyrosine kinase inhibitors.&#xD;
&#xD;
               -  CML with BCR-ABL mutation consistent with poor response to tyrosine kinase&#xD;
                  inhibition (e.g. T351I mutation).&#xD;
&#xD;
               -  CML with accelerated or blast phase with &lt;10% blasts after therapy.&#xD;
&#xD;
                    -  Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the&#xD;
                       EBMT consensus criteria&#xD;
&#xD;
                    -  Hodgkin lymphoma meeting both of the following criteria:&#xD;
&#xD;
               -  Responding to therapy prior to enrollment&#xD;
&#xD;
               -  Relapse after autologous bone marrow transplant or are ineligible for autologous&#xD;
                  bone marrow transplant.&#xD;
&#xD;
                  °Non-Hodgkin lymphoma meeting both of the following criteria:&#xD;
&#xD;
               -  Responding to therapy prior to enrollment.&#xD;
&#xD;
               -  Relapse after prior autologous bone marrow transplant or are ineligible for&#xD;
                  autologous bone marrow transplant.&#xD;
&#xD;
               -  Patients aged from birth through 65 years old are eligible.&#xD;
&#xD;
               -  Patients must have Karnofsky/Lanksy performance status ≥70%.&#xD;
&#xD;
               -  Cardiac left ventricular ejection fraction ≥50% at rest.&#xD;
&#xD;
               -  Serum bilirubin ≤ 2 mg/dL. Patients with Gilbert's disease or ongoing hemolytic&#xD;
                  anemia are acceptable if the direct bilirubin is ≤ 2 mg/dL.&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x ULN unless thought to be disease related&#xD;
&#xD;
               -  Estimated or measured creatinine clearance &gt; 50 mL/min/1.73 m^2 body surface&#xD;
                  area.&#xD;
&#xD;
               -  Adult patients and pediatric patients capable of performing pulmonary function&#xD;
                  studies must have hemoglobin adjusted pulmonary DLCO ≥50% of predicted.&#xD;
&#xD;
        Subject Exclusion Criteria:&#xD;
&#xD;
          -  Persons with a HLA matched sibling donor or a 8/8 allele level HLA-matched unrelated&#xD;
             donor.&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Persons with an infection that is not responding to antimicrobial therapy.&#xD;
&#xD;
          -  Persons who are seropositive for HIV.&#xD;
&#xD;
          -  Persons with active/detectable central nervous system malignancy.&#xD;
&#xD;
          -  Persons who do not meet the age and organ function criteria specified above.&#xD;
&#xD;
          -  Presence of psychiatric or neurologic disease, or lack of social support that limits&#xD;
             the patient's ability to comply with the treatment protocol including supportive care,&#xD;
             followup, and research tests.&#xD;
&#xD;
          -  Prior allogeneic hematopoietic cell transplantation are ineligible.&#xD;
&#xD;
          -  Patients with history of other malignancy within 5 years of study therapy are&#xD;
             ineligible with the following exceptions: Low grade prostate cancer (Gleason's ≤6)&#xD;
             treated with curative intent, breast ductal carcinoma in situ treated with curative&#xD;
             intent, or nonmelanomatous skin carcinomas.&#xD;
&#xD;
        Donor Inclusion and Exclusion Criteria:&#xD;
&#xD;
          -  Partially HLA-matched unrelated volunteers (allele level matched at 6-7 of 8 HLA loci:&#xD;
             -A, -B, -C, and -DRB1) are eligible.&#xD;
&#xD;
          -  Related, haploidentical donors are eligible.&#xD;
&#xD;
          -  Able to provide informed consent to the donation process&#xD;
&#xD;
          -  Meet standard criteria for donor collection as defined by the National Marrow Donor&#xD;
             Program Guidelines.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Shaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
  <keyword>α/β+ T-lymphocyte</keyword>
  <keyword>18-224</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

